Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | SCN1A | P35498 | 4/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239160 | 0.92 | POLB (0.44) | POLBSMN1; SMN2CSNK2A1SCDHRH3 | |
| SCHEMBL12239172 | 0.91 | SMN1; SMN2 (0.43) | POLBSMN1; SMN2CSNK2A1GPR119SCD | |
| SCHEMBL12239159 | 0.90 | SCD (0.49) | POLBSMN1; SMN2CSNK2A1SCDSCN1A | |
| SCHEMBL12239167 | 0.89 | UTS2R (0.46) | POLBSMN1; SMN2CSNK2A1GPR119SCD | |
| SCHEMBL12239164 | 0.88 | HRH1 (0.44) | SCDUTS2RACHEKCNH2 | |
| SCHEMBL12239163 | 0.87 | OPRK1 (0.43) | POLBSMN1; SMN2CSNK2A1HRH3UTS2R | |
| SCHEMBL12239158 | 0.86 | UTS2R (0.45) | SCN1ASCN8AUTS2RACHE | |
| SCHEMBL1006626 | 0.85 | GPR119 (0.50) | GPR119SCN1ASCN8AKCNH2 | |
| SCHEMBL1006677 | 0.85 | GPR119 (0.44) | GPR119SCDSCN1ASCN8AUTS2R | |
| SCHEMBL12239165 | 0.85 | DGAT2 (0.48) | SCN1ASCN8AUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | POLB 4770/4885SMN1; SMN2 3819/4885CSNK2A1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.